
 |
| Obesity Week |
 |
 |
|
|
United States |
|
News and comprehensive information about the prevention, diagnosis and treatment of obesity.
|
 |
|
|
|
| Related Site |
 |
 |
Fabry Community : Provides information and support for people with Fabry disease, their caregivers and families, and their health care providers.
Liver Amyloidosis : A gross specimen of a liver by Urbana Atlas of Pathology.
Cerebrotendinous Xanthomatosis : A description of this rare disease, its symptoms, diagnosis and treatment.
Wilson's Disease : A definition of this disease, clinical manifestations, diagnosis and treatment.
Facts on Hyponatremia : Article about over-hydration.
Menkes Disease : Medical information including pathophysiology, causes, clinical features, laboratory and histological findings. Also includes images.
Comprehensive Gaucher Treatment Center : Provides clinical evaluations for the diagnosis and treatment of patients with this disease. Information about the disease and the facility.
Gaucher Registry : Longitudinal, observational program that tracks the health outcomes of routine clinical practice for patients with Gaucher disease.
Fabry's Disease : About this disease its symptoms and possible complications, prognosis and treatment.
Heart - Amyloidosis : Picture of the heart affected by amyloidosis by the Urbana Atlas of Pathology.
|
|
|
 |
 |
 |
Health Tip: What's Behind Childhood Obesity (HealthDay)
HealthDay - (HealthDay News) -- Obesity is a major problem in the United
States, and children are no exception. Today's kids are spending more
hours watching TV, sitting at the computer or playing video games, and
less time being active. |
 |
Child Obesity Rates Going Up (HealthDay)
HealthDay - TUESDAY, March 2 (HealthDay News) -- New research finds that the
prevalence of obesity has grown in recent years among children aged 10 to
17, and certain kids are being especially hard hit. |
 |
Approval Expanded for Breast Cancer Drug Tykerb (HealthDay)
HealthDay - MONDAY, Feb. 1 (HealthDay News) -- The U.S. Food and Drug
Administration has expanded approval for Tykerb (lapatinib) to include
postmenopausal women with hormone- and HER2-positive advanced breast
cancer who require hormone therapy. |
|
|
 |